ADAM17 and neoplasm: Consistent with ADAM17 KO mice, CAR-T cells with ADAM17 inhibition displayed increased CD122 expression in both tumor (Fig. 6h) and draining LNs (supplementary Fig. 8i), as well as STAT5 phosphorylation after IL-2 stimulation ex vivo (Fig. 6i).